Abstract
Feline vaccine-associated sarcoma (VAS) is a biologically aggressive soft-tissue sarcoma that can develop at sites where inactivated feline vaccines have been administered. We showed that platelet-derived growth factor (PDGF) and its receptor (PDGFR) play a role in the growth of VAS cells. The presence of PDGFR-β was confirmed in each of five VAS cell lines evaluated, one non-vaccine-associated feline fibrosarcoma (FSA) cell line and a feline fibroblast-derived cell line. The PDGF/PDGFR signaling pathway was inhibited in the VAS cell lines and the FSA cell line using the tyrosine kinase inhibitor imatinib mesylate (formerly called STI-571). Imatinib inhibited PDGF-BB-induced autophosphorylation of PDGFR in VAS cells and feline FSA cells in vitro in a dose-dependent manner. Imatinib also significantly inhibited growth of feline VAS tumors in a murine xenograft model. Imatinib reversed the protective effect of PDGF-BB on growth inhibition by doxorubicin and carboplatin. PDGF-BB protected VAS cells from serum starvation and doxorubicin-induced apoptosis but not carboplatin-induced apoptosis, and imatinib eliminated this protection. These observations suggest that imatinib inhibits PDGFR tyrosine kinase activity in feline soft tissue sarcomas in vitro and inhibits tumor growth in a xenograft model.
Similar content being viewed by others
Abbreviations
- C/10:
-
Complete minimal essential medium supplemented with 10% FBS
- CPT:
-
Carboplatin
- DOX:
-
Doxorubicin
- EGF:
-
Epidermal growth factor
- FBS:
-
Fetal bovine serum
- FSA:
-
Fibrosarcoma
- HGF:
-
Hepatocyte growth factor
- IGF-1:
-
Insulin-like growth factor-1
- MTS:
-
3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
- PDGF:
-
Platelet-derived growth factor
- PDGFR:
-
Platelet-derived growth factor receptor
- PI:
-
Propidium iodide
- VAS:
-
Vaccine-associated sarcoma
References
Abdiu A, Wingren S, Larsson SE, Wasteson A, Walz TM (1999) Effects of human platelet-derived growth factor-AB on sarcoma growth in vitro and in vivo. Cancer Lett 141:39–45
Badache A, De Vries GH (1998) Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived growth factor (PDGF) receptors and are induced to proliferate by PDGF BB. J Cell Physiol 177:334–342
Barber LG, Sorenmo KU, Cronin KL, Shofer FS (2000) Combined doxorubicin and cyclophosphamide chemotherapy for nonresectable feline fibrosarcoma. J Am Anim Hosp Assoc 36:416–421
Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH, Alitalo K, Eriksson U (2001) PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol 3:512–516
Bregazzi VS, LaRue SM, McNeil E, Macy DW, Dernell WS, Powers BE, Withrow SJ (2001) Treatment with a combination of doxorubicin, surgery, and radiation versus surgery and radiation alone for cats with vaccine-associated sarcomas: 25 cases (1995–2000). J Am Vet Med Assoc 218:547–550
Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Regenass U, Lydon NB (1995) Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A 92:2558–2562
Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100–104
Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon ND (2000) Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139–145
Carew JS, Schmidt JA, Humphrey SA, Dickerson EB, Radinsky R, MacEwen EG (1999) Growth factor expression and vaccine-associated sarcoma tumorigenicity. 19th Annual Veterinary Cancer Society Conference, pp 11–13
Chun R, Garrett L, MacEwen EG (2001) Cancer chemotherapy. In: Withrow SJ, MacEwen EG (eds) Small animal clinical oncology, 3rd edn. W.B. Saunders, Philadelphia, pp 92–118
Couto CG, Macy DW (1998) Review of treatment options for vaccine-associated feline sarcoma. J Am Vet Med Assoc 213:1426–1427
Druker BJ, Lydon NB (2000) Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105:3–7
Druker BJ, Tamura S, Buchdunger E, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561–566
Dubielzig RR, Hawkins KL, Miller RE (1993) Myofibroblastic sarcoma originating at the site of rabies vaccination in a cat. J Vet Diagn Invest 5:637–638
Esplin DG, McGill LD, Meininger AC, Wilson SR (1993) Postvaccination sarcomas in cats. J Am Vet Med Assoc 202:1245–1247
Floege J, Johnson RJ, Alpers CE, Fatemi-Nainie S, Richardson CA, Gordon K, Couser WG (1993) Visceral glomerular epithelial cells can proliferate in vivo and synthesize platelet-derived growth factor B-chain. Am J Pathol 142:637–650
Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, Atkins RC, Nikolic-Paterson DJ (2001) PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 59:1324–1332
Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283–1316
Heldin CH, Ostman A, Ronstrand L (1998) Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1378:F79–113
Hendrick MJ (1991) Do injection site reactions induce fibrosarcomas in cats? J Am Vet Med Assoc 199:968
Hendrick MJ (1999) Feline vaccine-associated sarcomas. Cancer Invest 17:273–277
Hendrick MJ, Brooks JJ (1994) Postvaccinal sarcomas in the cat: histology and immunohistochemistry. Vet Pathol 31:126–129
Hendrick MJ, Goldschmidt MH, Shofer FS, Wang YY, Somlyo AP (1992) Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical identification of aluminum. Cancer Res 52:5391–5394
Hendrick MJ, Shofer FS, Goldschmidt MH, Haviland JC, Schelling SH, Engler SJ, Gliatto JM (1994) Comparison of fibrosarcomas that developed at vaccination sites and at nonvaccination sites in cats: 239 cases (1991–1992). J Am Vet Med Assoc 205:1425–1429
Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, Nister M (1992) Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52:3213–3219
Hershey AE, Sorenmo KU, Hendrick MJ, Shofer FS, Vail DM (2000) Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986–1996). J Am Vet Med Assoc 213:58–61
Kass PH, Barnes WG, Spangler WL, Chomel BB, Culbertson MR (1993) Epidemiologic evidence for a causal relation between vaccination and fibrosarcoma tumorigenesis in cats. J Am Vet Med Assoc 203:396–405
Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O’Reilly T, Buchdunger E, Black PM, Stiles CD (2000) Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60:5143–5150
Kobayashi T, Hauck ML, Dodge R, Page RL, Price GS, Williams LE, Hardie EM, Mathews KG, Thrall DE (2002) Preoperative radiotherapy for vaccine associated sarcoma in 92 cats. Vet Radiol Ultrasound 43:473–479
Krystal GW, Honsawek S, Litz J, Buchdunger E (2000) The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6:3319–3326
Leveen P, Claesson-Welsh L, Heldin CH, Westermark B, Betsholtz C (1990) Expression of messenger RNAs for platelet-derived growth factor and its receptors in human sarcoma cell lines. Int J Cancer 46:1066–1070
Li X, Eriksson U (2003) Novel PDGF family members: PDGR-C and PDGF-D. Cytokine Growth Factor Rev 14:91–98
Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M, Backstrom G, Hellstrom M, Bostrom H, Li H, Soriano P, Betsholtz C, Heldin CH, Alitalo K, Ostman A, Eriksson U (2000) PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2:302–309
Macy DW, Hendrick MJ (1996) The potential role of inflammation in the development of the postvaccine sarcomas in cats. Vet Clin North Am Small Anim Pract 26:103–109
Madewell BR, Griffey SM, McEntee MC, Leppert VJ, Munn RJ (2001) Feline vaccine-associated fibrosarcoma: an ultrastructural study of 20 tumors. Vet Pathol 38:196–202
Mauro MJ, O’Dwyer M, Heinrich MC, Druker BJ (2002) STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 20:325–334
McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ, Bar-Eli M (2002) Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 8:3584–3591
Mendelsohn J, Gabrilove J (1995) Growth factors in malignancy. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA (eds) The molecular basis of cancer. W.B. Saunders, Philadelphia, pp 432–459
Morrison WB, Sarr RM (2001) Vaccine-associated feline sarcomas. J Vet Diagn Invest 5:697–702
Nister M, Claesson-Welsh L, Eriksson A, Heldin CH, Westermark B (1991) Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J Biol Chem 266:16755–16763
Palman C, Bowen-Pope DF, Brooks JJ (1992) Platelet-derived growth factor receptor (beta-subunit) immunoreactivity in soft tissue tumors. Lab Invest 66:108–115
Poirier VJ, Thamm DH, Kurzman ID, Jeglum KA, Chun R, Obradovich JE, O’Brien RM III, Phillips BS, Vail DM (2002) Liposome encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. J Vet Intern Med 16:726–731
Robson MC, Phillips LG, Thomason A, Altrock BW, Pence PC, Heggers JP, Johnston AF, McHugh TP, Anthony MS, Robson LE (1992) Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers. Ann Plast Surg 29:193–201
Robson MC, Phillips LG, Thomson A, Robson LE, Pierce GF (1992) Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 339:23–25
Rodt SA, Ahlen K, Berg A, Rubin K, Reed RK (1996) A novel physiological function for platelet-derived growth factor-BB in rat dermis. J Physiol 495:193–200
Rubin BP, Schuetze SM, Eary FF, Norwood TH, Mirza S, Corad EU, Bruckner JD (2002) Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20:3586–3591
Sjoblom T, Shimizu A, O’Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A, Heldin CH (2001) Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61:5778–5783
Taniuchi K, Yamada Y, Nonomura A, Takehara K (1997) Immunohistochemical analysis of platelet-derived growth factor and its receptors in fibrohistiocytic tumors. J Cutan Pathol 24:393–397
Uren A, Merchant MS, Sun CJ, Vitolo MI, Sun Y, Tsokos M, Illei PB, Ladanyi M, Passaniti A, Mackall C, Toretsky JA (2003) Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing’s sarcoma cells. Oncogene 22:2334–2342
van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato DP, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421–1423
van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, Sciot R, Van Glabbeke M, Dimitrijevic S, Nielsen OS (2002) Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38 [Suppl 5]:S83–87
Weiner TM, Liu ET, Craven RJ, Cance WG (1994) Expression of growth factor receptors, the focal adhesion kinase, and other tyrosine kinases in human soft tissue tumors. Ann Surg Oncol 1:18–27
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported in part by the American Veterinary Medical Association Feline Sarcoma Task Force. Imatinib mesylate was provided by Novartis Pharmaceuticals, Inc.
Rights and permissions
About this article
Cite this article
Katayama, R., Huelsmeyer, M.K., Marr, A.K. et al. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother Pharmacol 54, 25–33 (2004). https://doi.org/10.1007/s00280-004-0780-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-004-0780-7